In 2022, the United States spent approximately $4.5 trillion on healthcare, a figure so staggering it represents nearly 17 percent of the national Gross Domestic Product. Every election cycle, we are treated to a familiar parade of promises from both sides of the aisle, pledging to lower premiums and dismantle the labyrinthine bureaucracy of medical billing.

Yet, despite the passage of the Affordable Care Act in 2010 and subsequent attempts at reform, the average family premium has climbed nearly 50% over the last decade. Why does a system that everyone claims is broken continue to function so profitably for those at the top?

The answer is not found in a single villain, but in a series of structural incentives that reward volume over value and complexity over clarity. If we want to understand why the cost of a simple saline drip can vary by 3,000 percent between two hospitals in the same city, we must look at the hidden architecture of the American medical industrial complex.

The Invisible Hand of the Middleman

When you pick up a prescription at a pharmacy, you likely assume the price is a direct negotiation between the drug manufacturer and your insurer. In reality, the most powerful players in the room are Pharmacy Benefit Managers (PBMs) like CVS Caremark, Express Scripts, and OptumRx.

These three entities control roughly 80 percent of the prescription drug market, acting as the gatekeepers between manufacturers and patients. While they were originally conceived to negotiate lower prices, they have morphed into opaque profit centers that thrive on high list prices.

PBMs earn "rebates" from drug makers in exchange for placing a drug on a preferred tier of an insurance formulary. Because these rebates are often calculated as a percentage of the drug’s list price, the PBM has a perverse financial incentive to favor more expensive drugs over cheaper generics.

This dynamic creates a "rebate trap" where the very entities meant to lower costs are actually driving them higher to pad their own margins. Much like how The Subscription Fatigue Everyone Ignored Is Finally Killing Your Apps, the healthcare system has hidden the true cost of its services behind a layer of recurring, obfuscated fees.

The lack of transparency in these negotiations means that the consumer—the patient—is the only person in the transaction who has no idea what the actual price is until the bill arrives. Is it any wonder that insulin prices skyrocketed for years while the PBMs reported record-breaking quarterly earnings?

The Administrative State of Medicine

If you walked into a hospital in 1970, the ratio of physicians to administrators was roughly one to one. Today, that ratio has shifted so dramatically that there are now roughly 10 administrators for every one doctor practicing medicine.

Since 1990, the number of healthcare administrators has grown by over 3,000 percent, while the number of physicians has grown by only 150 percent. This administrative bloat is not merely a byproduct of bureaucracy; it is a necessary response to a billing system designed to be intentionally confusing.

We have reached a point where the "back office" of healthcare costs as much as the actual care being provided to patients. A 2019 study published in the Annals of Internal Medicine estimated that administrative costs account for $812 billion annually, or more than $2,500 per person.

This phenomenon mirrors the systemic inefficiencies we see in other public sectors, such as The Real Reason Cities Are Failing to Fix Their Traffic Problems, where more spending rarely results in better infrastructure. In healthcare, this money isn't buying better outcomes; it’s buying more coders to argue with insurance companies over denied claims.

The sheer complexity of our multi-payer system requires an army of specialists to navigate the thousands of different codes and requirements for reimbursement. When the process of getting paid becomes more expensive than the service itself, the patient is the one who ultimately pays the "complexity tax."

Why Efficiency Is a Dirty Word in Hospital Mergers

Over the last twenty years, the American hospital landscape has undergone a massive wave of consolidation, with large health systems like HCA Healthcare and Ascension absorbing local community hospitals. Proponents of these mergers often argue that "economies of scale" will lead to greater efficiency and lower prices for patients.

However, decades of data from the Federal Trade Commission (FTC) suggest the exact opposite: when hospitals merge, prices go up, and quality often stagnates or declines. When a single health system controls a majority of the beds in a metropolitan area, they gain immense leverage over insurance companies.

This leverage allows them to demand higher reimbursement rates, which are then passed on to employers and employees in the form of higher premiums. A study by the University of California, Berkeley, found that hospital prices in highly concentrated markets were 12 percent higher than in competitive markets.

Even more concerning is the rise of "cross-market" mergers, where health systems buy hospitals in entirely different regions. While these hospitals don't compete for the same patients, the larger system can use its size to force insurers into "all-or-nothing" contracts across the entire state.

This monopolistic behavior is a primary reason why healthcare costs remain insulated from the traditional laws of supply and demand. If there is no competition, there is no incentive to lower prices, regardless of how much "efficiency" a merger promises on paper.

The Perverse Incentive of the Medical Loss Ratio

One of the most touted features of the Affordable Care Act was the Medical Loss Ratio (MLR), which requires insurers to spend 80 to 85 percent of premium dollars on actual medical care. On the surface, this seems like a brilliant way to cap profits and ensure that money is going toward healing people rather than executive bonuses.

However, this policy created an unforeseen and deeply perverse incentive for insurance companies to actually want healthcare costs to rise. If an insurer’s profit is capped at 15 percent of their total revenue, the only way to increase the dollar amount of that profit is to increase the total amount of spending.

Think about it: 15 percent of a $100 billion market is $15 billion, but 15 percent of a $200 billion market is $30 billion. If the insurer successfully negotiates lower prices with hospitals, their total revenue decreases, which in turn decreases the absolute dollar amount they are allowed to keep as profit.

This explains why insurance companies often put up only a performative fight against rising hospital costs or pharmaceutical prices. As long as they can pass those costs on to the consumer via premiums, the rising tide of healthcare spending lifts all corporate boats.

This structural reality is a major reason why The Real Reason Younger Voters Are Abandoning Both Major Parties is often tied to a sense of economic hopelessness. When the regulations meant to protect you actually incentivize the industry to charge you more, the political process starts to feel like a rigged game.

Private Equity and the Financialization of Care

In recent years, a new and aggressive player has entered the healthcare arena: private equity firms like Blackstone, KKR, and Apollo. These firms have spent billions of dollars acquiring everything from emergency room staffing companies to dermatology practices and dental chains.

The private equity model is simple: acquire a practice, load it with debt, aggressively cut costs, and increase revenue before selling it for a profit within five to seven years. In a healthcare setting, "increasing revenue" almost always means billing more intensively for the same services.

A 2023 study in JAMA found that hospitals acquired by private equity firms saw a 25 percent increase in complications for patients, alongside a significant rise in charges. When the primary goal of a medical practice is to meet the quarterly internal rate of return for a group of investors in New York, patient care inevitably becomes secondary.

Private equity was also the driving force behind the "surprise billing" crisis that plagued American ERs for years. Firms would buy physician groups, take them out of insurance networks, and then send patients massive bills for services they thought were covered.

While the No Surprises Act of 2022 has mitigated some of this, the financialization of care continues to drive up the baseline cost of medicine. When doctors are pressured to see more patients in less time and order more profitable tests, the entire system becomes more expensive and less personal.

The Political Inertia of the $4.5 Trillion Status Quo

Why don't our elected officials simply pass laws to fix these obvious flaws? To find the answer, one only needs to look at the lobbying data: the healthcare industry spends more on lobbying in Washington D.C. than any other sector, including defense and big tech.

In 2023 alone, the health products and services sector spent over $700 million on lobbying efforts. This money ensures that any legislation that might actually threaten the profitability of PBMs, hospital systems, or insurers is either watered down or killed in committee.

We are currently trapped in a cycle where the very entities profiting from the high costs are the ones writing the rules of the game. It is a classic example of regulatory capture, where the industry has become so large and so essential to the economy that it is effectively "too big to fail" or even to reform significantly.

Furthermore, the healthcare industry is the single largest employer in many congressional districts across the country. Any politician who proposes a plan that might reduce healthcare spending is immediately accused of "cutting jobs" or "closing local hospitals," making real reform a political third rail.

Is the American healthcare system broken? From the perspective of the patient paying $1,200 for a ten-minute consultation, the answer is an obvious yes. But from the perspective of the shareholders and executives of the Fortune 500 companies that dominate the sector, the system is working exactly as intended.

Until we address the fundamental reality that our system is built on a foundation of for-profit incentives rather than public health outcomes, the cost of care will continue its upward trajectory. We will continue to hear promises of reform every four years, while the bills in our mailboxes continue to grow larger, more complex, and more disconnected from the reality of the care we receive.